Alere Inc

Most Recent

• 

  .

  Company & Industry Overviews

  Abbott-Alere Deal Wins Conditional US Antitrust Approval

  The Federal Trade Commission recently announced the US antitrust approval for Abbott Laboratories’ (ABT) acquisition of Alere (ALR).

• 

  .

  Earnings Report

  What Were Abbott’s Key Growth Drivers for 2Q17?

  Abbott completed the acquisition of St. Jude Medical in January 2017. It contributed significantly to its 2Q17 sales.

• 

  .

  Miscellaneous

  Does Novartis See Much Potential for Its Surgical Business?

  In 2017, Novartis (NVS) has planned to conduct a review of its Alcon segment to evaluate the business’s growth potential.

• 

  .

  Company & Industry Overviews

  Alere’s Response to Abbott Laboratories’s Lawsuit to Terminate the Merger

  Alere (ALR) denied claims that any of the events that occurred during the last ten months would constitute any material change to the company’s value.

• 

  .

  Company & Industry Overviews

  A Brief Recap of the Abbott–Alere Deal Developments

  Three months after announcing a $5.8 billion deal in which Abbott Laboratories (ABT) would buy Alere (ALR), Alere rejected Abbott’s $50 million offer to end the deal. On December 7, Abbott sued Alere to terminate the deal.

• 

  .

  Earnings Report

  Abbott’s Stock Prices Fell despite Strong 3Q16 Results

  On October 19, Abbott Laboratories (ABT) released its 3Q16 earnings. After the announcement, its share price fell ~2% from $41.2 on October 18, 2016.

• 

  .

  Company & Industry Overviews

  The Rationale behind Johnson & Johnson’s Acquisition of Abbott Medical Optics

  On September 16, 2016, Johnson & Johnson announced the acquisition of Abbott Medical Optics, a subsidiary of Abbott Laboratories, and its stock fell ~0.3%.

• 

  .

  Company & Industry Overviews

  Waters Introduces Symphony, Its New Data Pipeline Software

  A top IHI performer on June 2, 2016, was Waters (WAT), which rose 0.9%. The company was in the news with the introduction of its new data pipeline software.

• 

  .

  Miscellaneous

  Rationale for the St. Jude Medical-Abbott Merger Transaction

  Abbott Labs is buying St. Jude Medical for about $30 billion in cash, stock, and assumed debt to become a dominant player in the cardiovascular health space.

• 

  .

  Miscellaneous

  The Alere-Abbott Labs Merger: Understanding the Alere Side

  Alere provides diagnostic solutions in the healthcare industry, primarily in infectious disease. Abbott Labs is buying Alere to boost its diagnostics line.

• 

  .

  Earnings Report

  Cepheid’s Revenue and Income Fell in 3Q15

  After its 3Q15 earnings report, Cepheid fell by 0.86% to close at $32.25 per share as of October 20, 2015, with a 4.8% fall in revenue in 3Q15.

• 

  .

  Fund Managers

  Steven Cohen’s Point72 Asset Management’s 3Q14 positions

  Point72 Asset Management’s portfolio decreased slightly to $13.2 billion in the third quarter—compared to $15.6 billion in the second quarter. The third quarter ended in September.